Taro gets FDA approval for biogeneric epilepsy drug

Industry sources: levetiracetam tablets had over $700 million in US sales in 2009.

Taro Pharmaceutical Industries Ltd. (Pink Sheets: TAROF) has received US Food and Drug Administration (FDA) approval for the company's Abbreviated New Drug Application (ANDA) for Levetiracetam tablets, a biogeneric version of Belgian biopharmaceutical company UCB SA's (Euronext: UCB) Keppra tablets for the treatment of epilepsy.

Taro received FDA approval for four dosages of the tablets: 250 mg, 500 mg, 750 mg, and 1000 mg. According to industry sources, levetiracetam tablets had over $700 million in US sales in 2009.

Taro's share closed at $10.01 on Wall Street yesterday.

Published by Globes [online], Israel business news - www.globes-online.com - on February 2, 2010

© Copyright of Globes Publisher Itonut (1983) Ltd. 2010

View comments in rows
Update by email about comments talkback
Your name
Please insert your name
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Twitter Facebook Linkedin RSS Newsletters גלובס Capital  Markets Conference 2017